Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 140

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 140
---
 as and when needed could have a negative impact on our financial condition and ability to pursue our business
strategies.

Our
consolidated financial statements have been presented on a going concern basis, which contemplates the realization of assets and the satisfaction
of liabilities in the normal course of business.

As
of June 30, 2024, we had cash and cash equivalents of £5.06 million.

We
have prepared cash flow forecasts and considered the cash flow requirement for our next three years, including the period twelve months
from the date of the approval of the financial statements. These forecasts show that further financing will be required during the course
of the next 12 months, assuming, inter alia, that certain development programs and other operating activities continue as currently planned. If
we do not secure additional funding before the end of the first quarter of 2025, we will no longer be a going concern and would likely
be placed in administration.

Our
forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement
and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the timing of clinical
trials. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner
than we currently expect. If we lack sufficient capital to expand our operations or otherwise capitalize on our business opportunities,
our business, financial condition and results of operations could be materially adversely affected.

If
we raise additional funds through the issuance of debt securities or additional equity securities, it could result in dilution to our
existing shareholders, increased fixed payment obligations and these securities may have rights senior to those of our Ordinary Shares
(including the Depositary Shares) and could contain covenants that would restrict our operations and potentially impair our competitiveness,
such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property
rights and other operating restrictions that could adversely impact our ability to conduct our business. Any of these events could significantly
harm our business, financial condition and prospects.

| 72 |

In our opinion, the environment
for financing of small and micro-cap biotech companies remains challenging. While this may present acquisition and/or merger opportunities
with other companies with limited or no access to financing, as noted above, any attendant financings by us are likely to be dilutive.
We continue to evaluate financing options, including those connected to